Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 6Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms 1Lymphoma 1Liposarcoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 4fludarabine phosphate 3fludarabine 3Methotrexate 3merphos 2Pentetic Acid 2Methylprednisolone 2Hydrocortisone 2Cyclophosphamide 2Biopsy 2revumenib 1pegaspargase 1ixazomib 1hydrocortisone hemisuccinate 1ethanolamine oleate 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Sulfamethoxazole 1Stem Cell Transplantation 1Specimen Handling 1Sodium Chloride 1Sirolimus 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Biphenotypic, Acute × ixazomib × Clear all
NCT02578511 2018-02-15

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Medical College of Wisconsin

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡